PT - JOURNAL ARTICLE ED - , TI - â–¼Naltrexone/bupropion for obesity AID - 10.1136/dtb.2017.11.0550 DP - 2017 Nov 01 TA - Drug and Therapeutics Bulletin PG - 126--129 VI - 55 IP - 11 4099 - http://dtb.bmj.com/content/55/11/126.short 4100 - http://dtb.bmj.com/content/55/11/126.full SO - Drug Ther Bull2017 Nov 01; 55 AB - â–¼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy.